Ptc Therapeutics (PTCT) Amortization of Deferred Charges (2015 - 2026)

Ptc Therapeutics' Amortization of Deferred Charges history runs 12 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 488.96% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $2.7 million, a 65.43% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 84.28% from the prior year.
• Amortization of Deferred Charges improved to $1.8 million in Q1 2026 per PTCT's latest filing, from $313000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $6.9 million in Q4 2024 and bottomed at -$5.6 million in Q4 2022.
• The 5-year median for Amortization of Deferred Charges is $300000.0 (2024), against an average of $514882.4.
• Across the five-year window, Amortization of Deferred Charges surged 2194.65% in 2024 and slumped 95.44% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at -$5.6 million in 2022, then surged by 105.34% to $299000.0 in 2023, then jumped by 2194.65% to $6.9 million in 2024, then slumped by 95.44% to $313000.0 in 2025, then surged by 462.62% to $1.8 million in 2026.
• Per Business Quant, the three latest PTCT Amortization of Deferred Charges figures stand at $1.8 million (Q1 2026), $313000.0 (Q4 2025), and $306000.0 (Q3 2025).